Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2011

View Archived Issues

Studies provide insight into TL-32711 activity and dosing

Phase I trial of Antisense Therapeutics product meets endpoint

Sanofi reports data from GetGoal Duo 1 study

Primary endpoint met in Toviaz trial

International team identifies potential therapeutic for cocaine addiction

Translational profiling of serotonergic neurons reveals new gene linked to autism

Phase II studies evaluate K-134 in peripheral arterial disease

New diacylglycerol O-acyltransferase 1 inhibitors show potential to treat obesity and/or diabetes

New inhibitors of fatty acid synthase presented

U.S. university extracts novel agents with antidiabetic potential from African shrub

Vertex Pharmaceuticals patents novel voltage-gated sodium channel antagonists

Novel immunomodulating and anti-inflammatory compounds described

BioLineRx reports final data from phase Ia BL-1021 trial

Horizon Pharma launches new combination tablet for rheumatoid arthritis and osteoarthritis

Novel GPR119 receptor agonists disclosed by Boehringer Ingelheim

TetraLogic Pharmaceuticals begins new phase I/II TL-32711 trial

Bristol-Myers Squibb divulges new potential therapeutics for hepatitis C

DM-199 increases C-peptide levels in animal model

Morphotek terminates phase III farletuzumab trial

Cyclacel Pharmaceuticals reports interim data from sapacitabine trials

Aradigm obtains U.S. patent for Pulmaquin and plans phase III development

Ono Pharmaceutical announces new launch in Japan

European Commission approves Takeda product for essential hypertension

Theratechnologies discontinues tesamorelin COPD program

ChemoCentryx begins new study of CCX-140 in diabetic nephropathy

FDA committee votes in favor of peginesatide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...